Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract: A method of predicting a health status of an integrated drive generator (IDG) includes determining an effective deviation across a plurality of IDG output frequencies for a given IDG operation period. The method includes correlating the effective deviation to an IDG capability to determine a health of the IDG. A system for predicting a health status of an integrated drive generator (IDG) includes an IDG and a generator control unit (GCU) operatively connected to the IDG to determine a plurality of IDG output frequencies for a given IDG operation period. The system includes a central processing unit (CPU) operatively connected to the GCU to receive the IDG output frequencies therefrom. The CPU is configured and adapted to determine an effective deviation across at least some of the plurality of IDG output frequencies for the given IDG operation period, and correlate the effective deviation to an IDG capability to determine a health of the IDG.

Abstract: A method of predicting a health status of an integrated drive generator (IDG) includes determining an effective deviation across a plurality of IDG output frequencies for a given IDG operation period. The method includes correlating the effective deviation to an IDG capability to determine a health of the IDG. A system for predicting a health status of an integrated drive generator (IDG) includes an IDG and a generator control unit (GCU) operatively connected to the IDG to determine a plurality of IDG output frequencies for a given IDG operation period. The system includes a central processing unit (CPU) operatively connected to the GCU to receive the IDG output frequencies therefrom. The CPU is configured and adapted to determine an effective deviation across at least some of the plurality of IDG output frequencies for the given IDG operation period, and correlate the effective deviation to an IDG capability to determine a health of the IDG.

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.